August 1, 2024 — On the theme of “Is there anything GLP-1s can’t do?” a new randomized controlled trial is coming at us from the Alzheimer’s Association International Conference. It showed promising signs that a GLP-1, liraglutide, might slow the progression of Alzheimer’s disease. Liraglutide is used under the brand name Victoza to treat type 2 diabetes. At higher […]
July 15, 2024 — What should we take away from yet another suggestion that semaglutide might cut the risk of dementia? An Unexpected Finding This latest hint was a surprise. It comes from research that aimed to measure the risk of neurological and psychiatric problems associated with taking semaglutide for type 2 diabetes. Riccardo De Giorgi and colleagues were […]
July 8, 2021 — This is seriously messed up. Let’s consider the case of two innovative new drugs and how health insurance will cover them. Each of them treats a chronic disease that can devastate a person’s health and quality of life. But these are different diseases and very different drugs. One offers a breakthrough in effectiveness. In fact, […]
February 10, 2019 — Sometimes things are not what they seem. That’s a problem when something slips into scientific literature that’s not exactly true. We offer a prime example today. Here we have two papers where an RCT – a randomized controlled study – is not properly randomized. Apparently, the investigators, reviewers, and editors for these papers weren’t too fussy about […]
April 11, 2015 — The answer is no. You better not count on obesity to protect you from Alzheimer’s disease, regardless of what you might read in the newspaper. A study just published in Lancet Diabetes and Endocrinology led the Washington Post to proclaim that ”being fat in middle age reduces risk of developing dementia.” Of course, this is not […]
